Trimetazidine HCl is used in angina pectoris and in ischaemia of neurosensoral tissue as in manieres disease. It will be much advantageous to present such drug in Rapid Disintegrating dosage form, as their administration is easier for the patient of angina attack. Bitter taste of the drug pose a main problem in patient compliance. Hence Eudragit EPO polymer was used for complexation with drug for overcoming taste problem. The Lyophilization method was used to form the drug polymer complex in a tablet. 1:3 ratio of the drug to polymer was effectively masked the bitter taste of drug. PVP were used in different ratios. 0.25% PVP forms the optimized tablet. FTIR studies were done to study the drug polymer interaction. Rapid Disintegrating Tablet was formulated in the blister packs using Freeze Drying Method. The tablets were evaluated for different evaluation parameters. The tablet batch TEP3 having 1:3 ratio of Drug: Eudragit EPO were selected as the optimized batches. The marketed formulation showed much longer disintegration time (205±0.04) as compared to the presented formulations. Also the dissolution of marketed tablet is more (t90 around 13 min) as compared to the prepared tablet (t90 for TEP3 and TEG3 around 2.5 min).Thus prepared tablet is superior to marketed formulation in term of disintegration time and dissolution behavior.
Cite this article:
Barokar A.A., Wagh R.D., Baviskar D.T., Shaikh T.J. Formulation and Characterization of Taste Masked Rapid Disintegrating Tablets of Trimetazidine HCl. Research J. Pharm. and Tech. 4(7): July 2011; Page 1098-1102.
Barokar A.A., Wagh R.D., Baviskar D.T., Shaikh T.J. Formulation and Characterization of Taste Masked Rapid Disintegrating Tablets of Trimetazidine HCl. Research J. Pharm. and Tech. 4(7): July 2011; Page 1098-1102. Available on: https://rjptonline.org/AbstractView.aspx?PID=2011-4-7-13